• Oct 23, 2026

  $24.40-5.54%

  Comparable pharmaceutical preparations companies moved -0.82% on average, with 4 of 6 falling and 1 rising [1]. VKTX's 5.54% drop was therefore much steeper than the cohort's average move and was not shared to the same degree [1].

  • 1Peer group

• Oct 22, 2026

  $25.83-2.08%

  Comparable pharmaceutical preparations companies moved -0.96% on average, with 4 of 6 falling [1]. VKTX fell 2.08%, a larger decline than the group average [1]. Volume was 0.5x its trailing 20-session average, and the session traded between 25.66 and 26.79 [2].

  • 1Peer group
  • 2Market data

• Oct 21, 2026

  $26.38-1.24%

  Viking's shares fell 1.24% alongside comparable pharmaceutical companies, which moved -1.50% on average [1]. Five of the six peers fell, so the decline was largely shared with the group [1]. Volume was 0.4x the trailing average [2].

  • 1Peer group
  • 2Market data

• Oct 20, 2026

  $26.71+6.63%

  Comparable pharmaceutical companies rose 2.69% on average, with all 6 advancing [2]. The company's 6.63% gain was larger than the cohort's move [2]. The Motley Fool reported that the company had initiated a pivotal Phase 3 trial of oral VK2735 [1]. Volume was 0.5x its trailing 20-session average [3].

  • 1The Motley Fool
  • 2Peer group
  • 3Market data

• Oct 19, 2026

  $25.05-0.48%

  Viking Therapeutics slipped 0.48% while comparable Pharmaceutical Preparations companies rose 1.79% on average, with 4 of 6 higher [1]. The move was therefore not shared by the cohort. Volume was 0.4x the trailing average [2].

  • 1Peer group
  • 2Market data

• Oct 16, 2026

  $25.17-8.04%

  Comparable pharmaceutical preparations companies fell 3.66% on average on the session, with 4 of 6 lower and 1 higher [1]. The stock's 8.04% drop was larger than the cohort's average decline, so it went further than the group [1].

  • 1Peer group

• Oct 15, 2026

  $27.37+7.46%

  Comparable pharmaceutical companies rose 2.61% on average, with all 6 of them higher [1]. The company's 7.46% gain was larger than the cohort's average advance. Volume was 0.5x its trailing 20-session average, and the session traded between 25.86 and 27.51 [2].

  • 1Peer group
  • 2Market data

Closing prices for VKTX. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.